← Back to Search

PARP Inhibitor

Pamiparib for Gastric Cancer

Phase 2
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 23 months
Awards & highlights

Study Summary

This trial will compare the effectiveness of BGB-290 to a placebo in treating gastric cancer that has progressed despite prior platinum-based chemotherapy.

Eligible Conditions
  • Gastric Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 23 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 23 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (PFS) by Investigator Assessment
Secondary outcome measures
Duration of Response (DOR)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Objective Response Rate (ORR)
+3 more

Side effects data

From 2021 Phase 1 & 2 trial • 116 Patients • NCT03150862
73%
Nausea
73%
Fatigue
45%
Headache
35%
Constipation
35%
Decreased appetite
35%
Alopecia
33%
Anaemia
33%
Vomiting
30%
Diarrhoea
28%
Dizziness
25%
Dysgeusia
23%
Weight decreased
20%
Hemiparesis
18%
Platelet count decreased
15%
Aphasia
15%
Urinary incontinence
15%
Seizure
15%
Anxiety
15%
Insomnia
15%
Neutrophil count decreased
15%
White blood cell count decreased
15%
Memory impairment
13%
Fall
13%
Abdominal pain
10%
Dry mouth
10%
Cough
10%
Agitation
10%
Blood creatinine increased
10%
Hyponatraemia
10%
Oedema peripheral
10%
Thrombocytopenia
10%
Confusional state
8%
Tinnitus
8%
Nasal congestion
8%
Vision blurred
8%
Aspartate aminotransferase increased
8%
Alanine aminotransferase increased
8%
Lymphocyte count decreased
8%
Pulmonary embolism
8%
Malaise
8%
Hypophosphataemia
8%
Back pain
8%
Visual field defect
5%
Lymphopenia
5%
Skin atrophy
5%
Ear pain
5%
Hypoacusis
5%
Flatulence
5%
Cognitive disorder
5%
Hypoaesthesia
5%
Haematuria
5%
Neutropenia
5%
Abdominal distension
5%
Dyspepsia
5%
Asthenia
5%
Gait disturbance
5%
Otitis media
5%
Upper respiratory tract infection
5%
Contusion
5%
Radiation skin injury
5%
Hyperglycaemia
5%
Hypokalaemia
5%
Partial seizures
5%
Irritability
5%
Dermatitis acneiform
5%
Stomatitis
3%
Cerebral cyst
3%
Suicide attempt
3%
Chest pain
3%
Dehydration
3%
Sinus congestion
3%
Hypertension
3%
Dyspnoea
3%
Eructation
3%
Nephrolithiasis
3%
Hiccups
3%
Pyrexia
3%
Hemiplegia
3%
Bronchitis
3%
Wound infection
3%
Brain oedema
3%
Dysarthria
3%
Hydrocephalus
3%
Nervous system disorder
3%
Ear discomfort
3%
Mental status changes
3%
Dry eye
3%
Oral candidiasis
3%
Oral herpes
3%
Non-cardiac chest pain
3%
Radiation injury
3%
Blood bilirubin increased
3%
Night sweats
3%
Muscle spasms
3%
Disturbance in attention
3%
Depression
3%
Postoperative wound infection
3%
Sepsis
3%
Apraxia
3%
Psychogenic seizure
3%
Vasogenic cerebral oedema
3%
Dysphagia
3%
Sinusitis
3%
Urinary tract infection
3%
Hypernatraemia
3%
Hypoalbuminaemia
3%
Arthralgia
3%
Groin pain
3%
Muscular weakness
3%
Myalgia
3%
Pain in extremity
3%
Hypersomnia
3%
Paraesthesia
3%
Tremor
3%
Pollakiuria
3%
Rhinitis allergic
3%
Dermatitis
3%
Dermatitis contact
3%
Pruritus
3%
Rash maculo-papular
3%
Deep vein thrombosis
3%
Neck pain
3%
Syncope
3%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + Temozolomide
Arm C: E- Pamiparib + Temozolomide 60 mg
Arm A: DE-Pamiparib 4 Wks + RT 6 Wks
Arm A: DE- Pamiparib 6Wks + RT 6 Wks
Arm C: DE - Pamiparib + Temozolomide 20 mg
Arm C: DE - Pamiparib + Temozolomide 40 mg
Arm 1Arm A: DE - Pamiparib 2 Wks + Radiation Therapy (RT) 6 Wks

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PamiparibExperimental Treatment1 Intervention
Participants received pamiparib orally.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pamiparib
2017
Completed Phase 2
~750

Find a Location

Who is running the clinical trial?

BeiGeneLead Sponsor
175 Previous Clinical Trials
28,678 Total Patients Enrolled
Study DirectorStudy DirectorBeiGene
1,206 Previous Clinical Trials
489,518 Total Patients Enrolled
Maggie Zhang, PharmDStudy DirectorBeiGene

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any potential adverse effects from the use of pamiparib?

"Our evaluation of pamiparib's safety has resulted in a score of 2, as it is currently being tested for efficacy during its Phase 2 trial."

Answered by AI

Have any prior experiments been conducted with pamiparib?

"Initial studies of pamiparib were conducted at Sarah Cannon Research Institute UK in 2017, and since then 18332 clinical trials have been finished. At present, 10 active tests are being administered with several located in Goshen, Indiana."

Answered by AI

How many sites are implementing this research study?

"The Goshen Center for Cancer Care in Indiana, the Oregon Health and Science University's Knight Cancer Institute - Hematology Medical Oncology in Portland, as well as Norton Cancer Institute of Louisville are all participating sites. An additional 13 locations are also partaking this study."

Answered by AI

Is enrollment still available for this clinical trial?

"Unfortunately, this investigation has already closed its participant recruitment period. It had originally been posted on July 23rd 2018 and was last updated October 26th 2022. Those interested in alternative trials can search for 490 clinical studies related to stomach cancer or 10 studies involving pamiparib that are still seeking participants."

Answered by AI

How many individuals have registered for this research project?

"This study is no longer open for participation. It was initially posted on July 23rd 2018 and the last update noted occurred on October 26th 2022. Currently, 490 studies are searching for participants with cancer of the stomach while 10 trials are seeking patients to trial pamiparib treatments."

Answered by AI

Do elderly people qualify for participation in this research experiment?

"In accordance with the inclusion criteria for this experiment, only those aged between 18 and 99 are eligible to participate."

Answered by AI

May I be considered a candidate for this experiment?

"The prerequisites for inclusion in this medical trial entail having a case of stomach cancer, being between the ages 18 and 99, and meeting additional criteria. 136 candidates are needed to complete the study."

Answered by AI

Is this experiment pioneering a new area of research?

"Currently, 10 trials of pamiparib are active in 115 cities and distributed across 18 countries. The first such trial was sponsored by Myriad Genetics, Inc., ran from 2017 to 2019 and involved 139 patients; following its completion, an additional 18332 experiments have been carried out."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
2018. "Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03427814.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top